Tempus AI Inc(TEM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 26 at 7:56 PM ET (Korea 10/27 08:56)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.44 | Insider Own | 40.02% | Shs Outstand | 175.0M | Perf Week | 4.38% |
| Market Cap | 12.12B | Forward P/E | - | EPS next Y | 87.01% | Insider Trans | -2.64% | Shs Float | 109.3M | Perf Month | -21% |
| Enterprise Value | 12.75B | PEG | - | EPS next Q | -0.09 | Inst Own | 55.69% | Short Float | 22.98% | Perf Quarter | 56.55% |
| Income | -0.25B | P/S | 8.46 | EPS this Y | 64.61% | Inst Trans | 4.28% | Short Ratio | 3.67 | Perf Half Y | 27.49% |
| Sales | 1.43B | P/B | 27.18 | EPS next 5Y | - | ROA | -12.75% | Short Interest | 25.12M | Perf YTD | 13.73% |
| Book/sh | 2.47 | P/C | 14.85 | EPS past 3/5Y | 10.57% 1.21% | ROE | -67.44% | 52W High | -28.08% ($93.38) | Perf Year | -24.73% |
| Cash/sh | 4.52 | P/FCF | - | Sales past 3/5Y | 58.29% 46.57% | ROIC | -13.56% | 52W Low | 64.73% ($40.77) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -21.05% | Gross Margin | 62.92% | Volatility(W/M) | 7.94% 8.32% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 8.9 | Sales Y/Y TTM | 50.43% | Oper. Margin | -18.92% | ATR (14) | 5.45 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.16 | EPS Q/Q | 112.51% | Profit Margin | -17.77% | RSI (14) | 46.68 | Recom | 2.3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.3 | Sales Q/Q | 21.56% | SMA20 | -5.51% ($71.08) | Beta | 3.63 | Target Price | $75.06 |
| Payout | - | Debt/Eq | 3.25 | Earnings | 2026/11/2 | SMA50 | -3.07% ($69.29) | Rel Volume | 0.55 | Prev Close | $67.61 |
| Employees | 3800 | LT Debt/Eq | 3.22 | EPS/Sales Surpr. | 71.99% 0.74% | SMA200 | 18.23% ($56.8) | Avg Volume(3M) | 6.85M | Price | $67.16 |
| IPO | 2024/6/14 | Option/Short | Yes/Yes | Trades | 35203 | Volume | 3,775,024 | Change | -0.67% |
A US precision medicine company that combines genetic testing, clinical data, and artificial intelligence to help diagnose and treat diseases such as cancer, the company is a precision medicine data and diagnostics business. It is growing rapidly on the back of its massive data assets but remains unprofitable.
Over the past 1 year, roughly in the middle
28% below its 1-year high.
Traded less than usual. That is 55% of its average volume.
Next earnings report: November 2
6 days to go.
TEM has a sound balance sheet but weak earning power
Of every $100 in sales, $18.92 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +64.6% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $846. Peers typically go for $166.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
23.0% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
ARKG ARK Genomic Revolution ETF 0.07% 
ARKK ARK Innovation ETF 0.05% 
ULTI REX IncomeMax Option Strategy ETF 0.05% 
HEAL Global X HealthTech ETF 0.04% 
EKG First Trust Nasdaq Lux Digital Health Solutions ETF 0.04% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
TEMT Tradr 2X Long TEM Daily ETF 30M 
TEMC Corgi TEM 2x Daily ETF - It ranks #2 of 41 in the industry
Based on market cap of $12B.
FAQ
What kind of company is TEM?
TEM belongs to the Healthcare sector and operates in the Health Information Services industry.
What is the market cap of TEM?
The market cap of TEM is approximately $12.1B, ranking 799 within its sector.
What is the 52-week high and low for TEM?
TEM has recorded a 52-week high of $93.38 and a low of $40.77.
